JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Recruiting

Phase 3

JNJ-90301900 & CetuximabJNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Sponsor:

Johnson & Johnson Enterprise Innovation Inc.

Code:

NCT04892173

Conditions

Locally Advanced Head and Neck Squamous Cell Carcinoma

Aged

Eligibility Criteria

Sex: All

Age: 60+

Healthy Volunteers: Not accepted

Interventions

JNJ-90301900 (NBTXR3)

Cetuximab

Radiation Therapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-27. This information was provided to ClinicalTrials.gov by Johnson & Johnson Enterprise Innovation Inc. on 2025-08-17.